Skip to main content
PMC home page
British Medical Journal logoLink to British Medical Journal
. 1976 Mar 13;1(6010):615–618. doi: 10.1136/bmj.1.6010.615

Failure of BCG immunostimulation to affect the clinical course of Burkitt's lymphoma.

I T Magrath, J L Ziegler
PMCID: PMC1639074  PMID: 766905

Abstract

A controlled randomised trial was carried out to evaluate the efficacy of BCG immunotherapy in preventing relapse in patients with Burkitt's lymphoma in whom remission had been induced with cyclophosphamide. Twenty-one patients were treated with BCG, and 19 were controls. Eleven patients in each group relapsed during a follow-up period long enough to make it unlikely that further relapses would occur. There were no significant differences in the length of remission or the site of relapse that could be attributed to treatment. Eleven patients died: of these none of the six patients in the BCG group but all of the five in the control group had stage D lymphomas. BCG treatment increased the rate of recovery from tumour-induced immunosuppression, but within the BCG group immunocompetence improved most rapidly in the patients who relapsed-a finding that appears to contradict the tenet retionalising the use of immunological adjuvants as treatment.

Full text

PDF
615

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baldwin R. W., Pimm M. V. BCG immunotherapy of pulmonary growths from intravenously transferred rat tumour cells. Br J Cancer. 1973 Jan;27(1):48–54. doi: 10.1038/bjc.1973.6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bast R. C., Jr, Zbar B., Borsos T., Rapp H. J. BCG and cancer. N Engl J Med. 1974 Jun 27;290(26):1458–1469. doi: 10.1056/NEJM197406272902605. [DOI] [PubMed] [Google Scholar]
  3. Bluming A. Z., Ziegler J. L., Fass L., Herberman R. B. Delayed cutaneous sensitivity reactions to autologous Burkitt lymphoma protein extract. Results of a prospective two and a half year study. Clin Exp Immunol. 1971 Dec;9(6):713–719. [PMC free article] [PubMed] [Google Scholar]
  4. Burkitt D. Long-term remissions following one and two-dose chemotherapy for African lymphoma. Cancer. 1967 May;20(5):756–759. doi: 10.1002/1097-0142(1967)20:5<756::aid-cncr2820200530>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  5. Hanna M. G., Jr, Snodgrass M. J., Zbar B., Rapp H. J. Histopathology of tumor regression after intralesional injection of Mycobacterium bovis. IV. Development of immunity to tumor cells and BCG. J Natl Cancer Inst. 1973 Dec;51(6):1897–1908. doi: 10.1093/jnci/51.6.1897. [DOI] [PubMed] [Google Scholar]
  6. Henle G., Henle W. Immunofluorescence in cells derived from Burkitt's lymphoma. J Bacteriol. 1966 Mar;91(3):1248–1256. doi: 10.1128/jb.91.3.1248-1256.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Henle G., Henle W., Klein G. Demonstration of two distinct components in the early antigen complex of Epstein-Barr virus-infected cells. Int J Cancer. 1971 Sep 15;8(2):272–282. doi: 10.1002/ijc.2910080212. [DOI] [PubMed] [Google Scholar]
  8. Klein G., Clifford P., Klein E., Smith R. T., Minowada J., Kourilsky F. M., Burchenal J. H. Membrane immunofluorescence reactions of Burkitt lymphoma cells from biopsy specimens and tissue cultures. J Natl Cancer Inst. 1967 Nov;39(5):1027–1044. [PubMed] [Google Scholar]
  9. Magrath I. T. Immunosuppression in Burkitt's lymphoma. I. Cutaneous reactivity to recall antigens: alterations induced by a tumour burden and by BCG administration. Int J Cancer. 1974 Jun 15;13(6):839–849. doi: 10.1002/ijc.2910130611. [DOI] [PubMed] [Google Scholar]
  10. Magrath I. T., Lwanga S., Carswell W., Harrison N. Surgical reduction of tumour bulk in management of abdominal Burkitt's lymphoma. Br Med J. 1974 May 11;2(5914):308–312. doi: 10.1136/bmj.2.5914.308. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Mathé G., Pouillart P., Lapeyraque F. Active immunotherapy of L1210 leukaemia applied after the graft of tumour cells. Br J Cancer. 1969 Dec;23(4):814–824. doi: 10.1038/bjc.1969.101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Parr I. Response of syngeneic murine lymphomata to immunotherapy in relation to the antigenicity of the tumour. Br J Cancer. 1972 Jun;26(3):174–182. doi: 10.1038/bjc.1972.24. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Prehn R. T. The immune reaction as a stimulator of tumor growth. Science. 1972 Apr 14;176(4031):170–171. doi: 10.1126/science.176.4031.170. [DOI] [PubMed] [Google Scholar]
  14. Ziegler J. L., Bluming A. Z., Fass L., Morrow R. H., Jr Relapse patterns in Burkitt's lymphoma. Cancer Res. 1972 Jun;32(6):1267–1272. [PubMed] [Google Scholar]
  15. Ziegler J. L., Magrath I. T. BCG immunotherapy in Burkitt's lymphoma: preliminary results of a randomized clinical trial. Natl Cancer Inst Monogr. 1973 Dec;39:199–202. [PubMed] [Google Scholar]
  16. Ziegler J. L., Morrow R. H., Jr, Fass L., Kyalwazi S. K., Carbone P. P. Treatment of Burkitt's tumor with cyclophosphamide. Cancer. 1970 Aug;26(2):474–484. doi: 10.1002/1097-0142(197008)26:2<474::aid-cncr2820260232>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES